Midatech makes board change
This article was originally published in Scrip
Executive Summary
Midatech Pharma has announced that Jeff Brown is stepping down from its board of directors, following the company's IPO, to pursue other business interests. The change is effective from 30 April 2015. Midatech, headquartered in Oxford, UK, has a pipeline of product candidates in clinical and preclinical development in the key therapeutic areas of diabetes, cancer and neurological/ophthalmological diseases. The company floated on the AIM Market of the London Stock Exchange in December 2014.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.